티움바이오 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 김훈택, was filed 24 Jun 2026.
Who traded when
BuySaleSince the insiders bought
- +11.6%Entry ₩5,500 · Close at T+90 ₩6,140
- +11.6%Entry ₩5,500 · Close at T+90 ₩6,140
- +155.1%Entry ₩5,150 · Close at T+365 ₩13,140
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 70,214 sharesShareKRXDART:20260624000001Canonical exit: 22 Sept 2026 (T+90)
- 30,476 sharesKRXDART:20260424000609
- ●Executives0DART
- Other0DART
- 6,000 sharesShareKRXDART:20250926000701Canonical exit: 25 Dec 2025 (T+90)
- 3,000 sharesShareKRXDART:20250926000716Canonical exit: 25 Dec 2025 (T+90)
- 28,571 sharesShareKRXDART:20250707000279Canonical exit: 5 Oct 2025 (T+90)
- 2,574,623 sharesKRXDART:20250428000657
- 900,000 sharesShareKRXDART:20250428000647Canonical exit: 27 Jul 2025 (T+90)
- 908,577 sharesKRXDART:20250428000674Canonical exit: 20 Jul 2025 (T+90)
- ●Executives0DART
- 10,000 sharesShareKRXDART:20241120000066Canonical exit: 18 Feb 2025 (T+90)
- 37,000 sharesShareKRXDART:20241111000068Canonical exit: 9 Feb 2025 (T+90)
- ShareKRXDART:20240521000112Canonical exit: 15 Aug 2024 (T+90)
- 2,574,623 sharesKRXDART:20240510000014
- ShareKRXDART:20240510000011
- ShareKRXDART:20231026000223
- ShareKRXDART:20230731000077
- ShareKRXDART:20230727000094
- ShareKRXDART:20230417000081
- ShareKRXDART:20230417000022
- 2,574,623 sharesKRXDART:20230417000089
- ●Executives0DART
- 370,000 sharesKRXDART:20230106000450
25 of 38 declarations
About 티움바이오
At 티움바이오, a Korean health care company on the Korea Exchange valued at KRW 126.6 billion, purchases and sales cancel out in number: 9 of each, so 50% purchases, with no amount stored. 김훈택 (대표이사) accounts for 20 of the 36 filings, with 6 purchases and 2 sales.
The fund 한국투자글로벌제약산업육성사모투자전문회사 (대량보유자, large holder) filed 7 times, every one a sale. 티움바이오 itself signed 6. 송인영 (부사장, vice president) and 김선미 (연구위원, 상무대우) made one purchase each. On September 26, 2025, 2 filers bought on the same day. Insiders and declared holders own 32.4% of the capital, and 18 filings are neither purchases nor sales.
Read moreShow less
Published from March 16, 2021 to June 24, 2026, the filings are spread fairly evenly: 9 in 2021, 8 in 2023, 7 in 2025 and 3 in 2026. The last twelve months bring 3 filings, one purchase and one sale. Median publication delay, all filings: 3 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
